Cardiovascular pharmacogenomics is a cutting-edge field that explores the intersection of genetics and cardiovascular medicine. It focuses on how an individual's genetic makeup influences their response to cardiovascular drugs, aiming to optimize treatment outcomes and minimize adverse effects. By studying the genetic variations that affect drug metabolism, efficacy, and toxicity, researchers in cardiovascular pharmacogenomics seek to tailor medication regimens to each patient's unique genetic profile. This personalized approach holds the potential to enhance the effectiveness of cardiovascular therapies, reduce the likelihood of side effects, and improve overall patient outcomes. As our understanding of the human genome continues to advance, cardiovascular pharmacogenomics promises to play a crucial role in the evolution of precision medicine, bringing us closer to more individualized and targeted treatments for cardiovascular diseases.
Title : Surgical fetal stem cells implantation in heart failure patients long term results at 14 years
Federico Benetti, Benetti Foundation, Argentina
Title : Exploring new biomarkers of cardiomyopathy
Shuping Zhong, University of Southern California, United States
Title : The development of human relaxin-2 for heart failure with preserved ejection fraction, HFpEF
Thomas Bernd Dschietzig, Relaxera GmbH & Co. KG, Germany
Title : Cancer and cardiovascular diseases: Common pathogenesis mechanisms and risk factors
Mekhman N Mamedov, National Research Center for Preventive Medicine, Russian Federation
Title : Pulse field ablation for atrial fibrillation complications: What do we know yet
Narendra Kumar, HeartbeatsZ Academy, United Kingdom
Title : Lipoprotein (a): The hidden cardiovascular risk
Syed Raza, Awali Hospital, Bahrain